Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Susan Lerner, MS, Ohad Benjamini, MD, Xuemei Wang, MS, Michael J. Keating, MD

Blood (2012) 120 (21): 2900.

https://doi.org/10.1182/blood.V120.21.2900.2900

Published: 2012

Journal Articles

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL.

Young Kwang Chae, MD, MPH, Long Xuan Trinh, Michael J. Keating, MD, Zeev Estrov, MD, PhD

Blood (2012) 120 (21): 2904.

https://doi.org/10.1182/blood.V120.21.2904.2904

Published: 2012

Journal Articles

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Lorenzo Falchi, MD, Long Xuan Trinh, Edith M. Marom, MD, Mylene Truong, MD, Ellen Schlette, MD, Rachel L. Sargent, MD, Xuemei Wang, MS, Susan C. Smith, Susan Lerner, MS, Michael J. Keating, MD, Alessandra Ferrajoli, MD

Blood (2012) 120 (21): 927.

https://doi.org/10.1182/blood.V120.21.927.927

Published: 2012

Journal Articles

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Ohad Benjamini, MD, Xuemei Wang, MS, Susan Lerner, MS, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 3931.

https://doi.org/10.1182/blood.V120.21.3931.3931

Published: 2012

Journal Articles

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Preetesh Jain, MD, DM, PhD, Long Xuan Trinh, Ohad Benjamini, MD, Susan Lerner, MS, Xuemei Wang, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Zeev Estrov, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Lynne V. Abruzzo, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 2890.

https://doi.org/10.1182/blood.V120.21.2890.2890

Published: 2012

Journal Articles

Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),

Maro Ohanian, DO, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Srdan Verstovsek, MD, PhD, Gautam Borthakur, Farhad Ravandi, MD, Guillermo Garcia-Manero, Elizabeth M Burton, Long Xuan Trinh, Alessandra Ferrajoli, MD, Elias Jabbour, Tapan Kadia, Jorge E. Cortes

Blood (2011) 118 (21): 3779.

https://doi.org/10.1182/blood.V118.21.3779.3779

Published: 2011

Journal Articles

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

Francesco Paolo Tambaro, MD, PhD, Guillermo Garcia-Manero, Stefan Faderl, MD, Susan O'Brien, MD, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Long Xuan Trinh, Susan Lerner, MS, BA, Hagop M. Kantarjian, Michael J Keating, MD, William G. Wierda, MD, PhD

Blood (2011) 118 (21): 981.

https://doi.org/10.1182/blood.V118.21.981.981

Published: 2011

Journal Articles

Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)

Theresa Liu-Dumlao, MD, Hagop M. Kantarjian, Alfonso Quintas-Cardama, MD, Elias Jabbour, Jan A. Burger, MD, PhD, Yesid Alvarado, MD, Elizabeth M Burton, Long Xuan Trinh, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Susan O'Brien, MD, Jorge E. Cortes

Blood (2011) 118 (21): 2761.

https://doi.org/10.1182/blood.V118.21.2761.2761

Published: 2011

NARROW

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Concurrent Use of Aspirin with the Fludarabine, Cyclophophamide, Rituximab (FCR) Regimen Improves Outcome in Patients with Relapsed/Refractory CLL.

Characteristics and Prognosis of Patients with Aggressive Chronic Lymphocytic Leukemia and Richter's Transformation: Correlation Between FDG/PET, Histology and Clinical Outcomes

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP),

Acute Leukemia and Myelodysplastic Syndrome: Outcomes in Patients with Chronic Lymphocytic Leukemia (CLL) At MD Anderson Cancer Center (MDACC)

Clinical Significance of Myelosuppression Associated with the Use of Dasatinib and Nilotinib As Initial Therapy in Chronic Phase (CP) of Chronic Myeloid Leukemia (CML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only